Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its earnings results on Thursday. The biotechnology company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08, reports. The firm had revenue of $67.77 million during the quarter, compared to analyst estimates of $59.07 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH opened at $8.32 on Friday. The firm has a fifty day simple moving average of $7.13 and a two-hundred day simple moving average of $6.12. Aurinia Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $10.05. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1.19 billion, a P/E ratio of -55.47 and a beta of 1.45.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently made changes to their positions in AUPH. Stonepine Capital Management LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $1,713,000. Cetera Advisors LLC raised its holdings in Aurinia Pharmaceuticals by 18.9% during the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 9,547 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Aurinia Pharmaceuticals by 15.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 5,079 shares during the period. Vanguard Group Inc. lifted its position in Aurinia Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after buying an additional 21,119 shares during the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter worth $158,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.